Genix Pharmaceuticals Corporation (GENPF)

USD 0.04

(0.0%)

Market Cap (In USD)

2.36 Million

Revenue (In USD)

12.34 Thousand

Net Income (In USD)

-4.39 Million

Avg. Volume

2290.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.0138-0.047
PE
-
EPS
-
Beta Value
-0.434
ISIN
CA37232A1093
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sina Salehi Pirooz
Employee Count
-
Website
https://www.genixpharm.com
Ipo Date
2020-02-18
Details
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and drops. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.